Agilent Technologies, BIA Separations GmbH sign agreement giving Agilent access to BIA Separations' bio-monolitic technology

05-Jun-2008

Agilent Technologies Inc. and BIA Separations GmbH announced the signing of an agreement that gives Agilent access to BIA Separations' bio-monolithic technology. Agilent plans to commercialize analytical HPLC bio-monolith columns with strong and weak ion-exchange phases and a Protein A phase. BIA Separations currently provides their preparative scale CIM(r) disk and process scale CIM(r) tube bio-monolithic products for purification and bioconversion of bio-molecules.

"Having access to the bio-monolithic technology allows Agilent to provide enabling solutions for the analytical separation of virus particles, plasmid DNA, antibodies and other macro bio-molecules," said Helen Stimson, vice president and general manager of Agilent's Global Columns and Supplies Solutions. "This technology, when applied at the analytical scale, will improve bio-drug characterization in development and allow QA/QC and process control labs to better monitor and characterize the production of biologics."

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous